证券代码：600161 证券简称：天坛生物 公告编号：2025-058 公司已于 2025 年 12 月 31 日召开第九届董事会第二十八次会议，审议通过 《关于增补董事的议案》，同意提名梁红军先生为公司第九届董事会董事，任期 至第九届董事会换届。本事项尚需提交将于 2026 年 1 月 16 日召开的公司 2026 年第一次临时股东会审议。详见同日披露的《北京天坛生物制品股份有限公司第 九届董事会第二十八次会议决议公告》（2025-059）和《北京天坛生物制品股份 有限公司关于召开 2026 年第一次临时股东会的通知》（2025-061）。 特此公告。 北京天坛生物制品股份有限公司 2025 年 12 月 31 日 一、提前离任的基本情况 姓名 离任职务 离任时间 原定任期 到期日 离任原因 是否继续在上 市公司及其控 股子公司任职 是否存在未 履行完毕的 公开承诺 张洁明 董事 2025 年 12 月 31 日 2026 年 5 月 24 日 工作调整 否 否 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京天坛生物制 ...

重要内容提示： 是否需要提交股东会审议：是 日常关联交易对上市公司的影响：符合公司经营业务的发展需要，有利 于公司正常生产经营活动的开展及资源的合理配置，公司与关联方间的交易遵循 公平、公正的原则，交易定价公允、合理，不存在损害公司和其他股东利益的情 形。 需要提请投资者注意的其他事项：无 证券代码：600161 证券简称：天坛生物 公告编号：2025-060 北京天坛生物制品股份有限公司日常关联交易公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （一）日常关联交易履行的审议程序 北京天坛生物制品股份有限公司（以下简称"公司"）于2025年12月31日召 开第九届董事会第二十八次会议，以4票同意，0票反对，0票弃权的表决结果， 审议通过《关于2026年度日常关联交易预计的议案》，4名关联董事回避表决。根 据《上海证券交易所股票上市规则》及《公司章程》规定，本次日常关联交易尚 需提交公司股东会审议，关联股东需回避表决。 本议案已经独立董事会议事前认可。独立董事会议就本关联交易事项发表意 见如下：本次日常关联交易事项符合公司 ...

证券代码：600161 证券简称：天坛生物 公告编号：2025-061 北京天坛生物制品股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 （一）股东会类型和届次 2026年第一次临时股东会 （二）股东会召集人：北京天坛生物制品股份有限公司董事会 （三）投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结 合的方式 （四）现场会议召开的日期、时间和地点 召开的日期时间：2026 年 1 月 16 日 14 点 30 分 召开地点：北京市朝阳区双桥路乙 2 号院会议室 （五）网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 1 月 16 日 至2026 年 1 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票 ...

北京商报讯（记者 王寅浩 宋雨盈）12月19日，天坛生物发布公告称，公司下属成都蓉生药业有限责任 公司研制的"注射用重组人凝血因子Ⅷ-Fc融合蛋白"于近日正式开展Ⅲ期临床试验。公告显示，该产品 适用于血友病A患者出血的控制和预防，以及手术出血预防，但不适用于治疗血管性血友病。 ...

格隆汇12月19日丨天坛生物(600161.SH)公布,北京天坛生物制品股份有限公司下属成都蓉生研制的"注射 用重组人凝血因子Ⅷ-Fc 融合蛋白"于近日正式开展Ⅲ期临床试验。 成都蓉生"注射用重组人凝血因子Ⅷ-Fc 融合蛋白"产品后续尚需完成Ⅲ期临床试验、提交药品上市许可 申请、通过国家药品监督管理局药品审评中心审评及国家药品监督管理局审批、获得药品注册证书等审 批程序，方可实现生产及上市销售。药品的研发是一项长期工作，存在诸多内外部不确定因素，敬请广 大投资者注意投资风险。 ...

北京天坛生物制品股份有限公司 证券代码：600161 证券简称：天坛生物 公告编号：2025-057 关于下属企业药品临床试验进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司下属成都蓉生药业有限责任公司（以下简称 "成都蓉生"）研制的"注射用重组人凝血因子Ⅷ-Fc 融合蛋白"于近日正式开 展Ⅲ期临床试验。现将有关信息披露如下： 一、 概况 （一） 产品信息 | 产品 | 适应症 | 获得临床试验批准 | 规格 | 注册 | 剂 | 研发 | | --- | --- | --- | --- | --- | --- | --- | | 名称 | | 通知书时间和编号 | | 分类 | 型 | 投入 | | | 本品适用于血友病A患者出血 的控制和预防。 | | | | | | | 注射用重 | 本品适用于血友病A患者的手 | 年 月 日 | | 治疗 | 注 | | | 组人凝血 | | 2023 12 19 | 250IU/瓶 | 用生 | | 9868.32 | | | 术出血预防。 | ...

（原标题：天坛生物12月12日大宗交易成交381.21万元） 天坛生物12月12日大宗交易平台出现一笔成交，成交量23.33万股，成交金额381.21万元，大宗交易成交 价为16.34元。该笔交易的买方营业部为中信证券股份有限公司深圳深南中路中信大厦证券营业部，卖 方营业部为机构专用。 两融数据显示，该股最新融资余额为14.87亿元，近5日增加1033.22万元，增幅为0.70%。 据天眼查APP显示，北京天坛生物制品股份有限公司成立于1998年06月08日，注册资本197737.1446万 人民币。（数据宝） 12月12日天坛生物大宗交易一览 | 成交量 | 成交金 | 成交价 | 相对当日 | | | | --- | --- | --- | --- | --- | --- | | （万 | 额 | 格 | 收盘折溢 | 买方营业部 | 卖方营业 | | | （万 | | 价 | | 部 | | 股） | 元） | （元） | （%） | | | | 23.33 | 381.21 | 16.34 | 0.00 | 中信证券股份有限公司深圳深南中路中信大厦证券营 业部 | 机构专用 | 注：本文系新闻报道，不 ...

Group 1: International Medicine - International Medicine plans to raise up to approximately 1.008 billion yuan through a private placement of A-shares to no more than 35 specific investors [1] - The raised funds will be allocated to three main projects: Smart Health and Elderly Care project (total investment of about 751 million yuan, with approximately 638 million yuan from the raised funds), Phase II of the Proton Therapy Center (total investment of 99.93 million yuan, with 99.93 million yuan from the raised funds), and working capital (total investment of 270 million yuan, with 270 million yuan from the raised funds) [1] Group 2: Zhongtai Securities - Zhongtai Securities reports that the innovative drug sector remains the most important theme in the pharmaceutical industry, with recent adjustments leading to a more reasonable valuation and increased safety margins [2] - The report suggests that the innovative drug sector has entered a favorable allocation window following a correction, and highlights structural rotation opportunities within the sector [2] Group 3: Zhongsheng Pharmaceutical - Zhongsheng Pharmaceutical's subsidiary has received approval for clinical trials of the innovative peptide drug RAY1225 for the treatment of Metabolic Associated Steatotic Hepatitis (MASH) [3] - The approval is significant as there are currently no approved drugs for this condition in the domestic market, indicating a clear market demand and considerable potential [3] Group 4: Tiantan Biological - Tiantan Biological's "Human Prothrombin Complex" has completed Phase III clinical trials, showing significant improvement in coagulation factor levels and bleeding symptoms in patients with Hemophilia B [4] - The positive results from the clinical trials provide a critical foundation for the product's market application, marking an important advancement in the field of blood products [4]

Core Viewpoint - Tian Tan Biological announced the completion of Phase III clinical trials for its "Prothrombin Complex Concentrate," which shows significant efficacy in treating hemophilia B and related coagulation disorders [1] Group 1: Clinical Trial Results - The Prothrombin Complex Concentrate is designed to treat congenital and acquired deficiencies of coagulation factors II, VII, IX, and X, including hemophilia B, anticoagulant overdose, and vitamin K deficiency [1] - Clinical trial results indicate that the infusion of this product significantly increases the levels of coagulation factors II, VII, IX, and X in hemophilia B patients, thereby improving their coagulation function and alleviating bleeding symptoms [1]

Group 1 - China Pacific Insurance has received approval from the financial regulatory authority for Wang Yuhua to serve as a director [1] - Shanghai Bank announced that the regulatory authority has approved Chen Lei's qualification as vice president [2] - Shanghai HuGong has decided to terminate the "Aerospace Equipment Manufacturing Base" fundraising project due to significant changes in project feasibility [3] Group 2 - Dongwang Times plans to reduce its stake by up to 1.20% through share sales [4] - Zhinancun intends to increase its capital by 100 million yuan in its wholly-owned subsidiary, Maigao Securities [5] - Jinxinnong reported a sales revenue of 115 million yuan from pig sales in November [6] Group 3 - Tiantan Biological has completed the Phase III clinical trial of its human prothrombin complex, showing good efficacy and safety for hemophilia B patients [7] - Beijete's subsidiary has signed a framework agreement for equity acquisition to gain control of Yunnan Wenye Nonferrous Metals [8] - Zhongsheng Pharmaceutical's RAY1225 injection has received approval for a new clinical trial indication for treating metabolic-associated fatty liver disease [9] Group 4 - Enhua Pharmaceutical's hydrochloride sulpiride tablets have passed the consistency evaluation for generic drugs [10] - Shenkong Co. plans to invest 60 million yuan in a semiconductor industry fund [11] - Lianhuan Pharmaceutical's subsidiary has received approval for its drug to pass the consistency evaluation for generic drugs [12] Group 5 - Dazhong Transportation has received approval to issue debt financing tools totaling 4.5 billion yuan [13] - Jintian Titanium Industry plans to invest 50 million yuan in an industry merger and acquisition fund [14] - Changchun Gas has committed over 1.7 billion yuan to gas facility upgrades [15] Group 6 - Laimei Pharmaceutical's innovative anti-cancer drug "Nano Carbon Iron" has received approval for clinical trials [16] - Longquan Co. has signed supply contracts worth approximately 50.76 million yuan for nuclear power components [17] - Igor plans to distribute a cash dividend of 1 yuan per 10 shares [18] Group 7 - Xingfa Group's subsidiary has signed a processing agreement for 80,000 tons of lithium iron phosphate [20] - Yunjigroup's director Wang Wanfeng has resigned for personal reasons [21] - Saiseng Pharmaceutical's application for the listing of a new drug has been accepted by the regulatory authority [22] Group 8 - Xinhua Medical has obtained registration certificates for two new medical devices [23] - Chaoying Electronics plans to invest 100 million USD in its Thai subsidiary for an AI circuit board expansion project [24] - Suzhou Planning's application to acquire 100% of Dongjin Aviation has been accepted by the Shenzhen Stock Exchange [25]